Brady Corp agrees to acquire Gravotech Holding for €123M (~$133M)

BRADY CORP

Purchase price €123M (~$133M); funded through cash on hand and existing credit facility.
Gravotech is a leader in marking/engraving; 2023 sales €112M (~$121M).
Expected to close by July 31, 2024, subject to French works council and regulatory clearances.
Adds direct part marking and engraving to Brady's product identification offering.
Excluding acquisition costs, EPS impact expected to be immaterial for FY ending July 31, 2024.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

BRADY CORP entered into Put Option Letter with MML Capital Europe VI II S.A. and other institutional and individual holders (collectively, the "Sellers") valued at approximately EUR 123 million (approximately USD 133 million) (effective 2024-03-15).

Action: entry
Agreement: asset purchase
Counterparty: MML Capital Europe VI II S.A. and other institutional and individual holders (collectively, the "Sellers")
Value: approximately EUR 123 million (approximately USD 133 million)
Effective: 2024-03-15

Exact text from the filing

On March 15, 2024, Braton Europe S.A.R.L., a wholly-owned subsidiary of Brady Corporation (the “Company”), entered into a Put Option Letter (the “Put Option Letter”) with MML Capital Europe VI II S.A. and other institutional and individual holders (collectively, the “Sellers”), which own directly or indirectly 100% of the securities issued by Gravotech Holding (“Gravotech”), a French limited liability company (société par actions simplifiée).

View on SEC.gov

556 material agreements filed in the last 30 days. Browse all material agreements →

BRADY CORP filing history →

Source: SEC EDGAR

accession 0000746598-24-000012

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.